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• Genetic haemochromatosis (GH) is the most common inherited genetic 
disorder in Caucasians (Bacon et al. 2011). 
• Worldwide distribution but commonly affects Northern Europeans, 
especially those with Celtic or Nordic descent; ratio of approximately 1:220-
250 people (Phatak, Bonkovsky and Kowdley 2008; Adams et al. 2005).
• The proportion of people diagnosed with this condition in Britain and Ireland 
is higher; approximately 1 in 200 British Liver Trust {BLT} 2017).
• Despite GH being the most common genetic disorder, approximately only 
1:5000 people are diagnosed with GH, making it an under diagnosed 
condition (BLT 2017).
• GH causes the body to absorb more iron from the diet than is required and as 
the liver is the main storage for iron, any excess is transported there (Powell 
Deckington and Deugnier 2016). 
• Over time, GH causes systemic iron overload not only within the liver but 
within other internal organs such as pancreas, heart and joints; eventually 
causing inflammation and tissue damage, which could lead to heart disease 
and diabetes. 
• Liver disease usually precedes disease in other affected organs (Ulvik 2015) 
which can lead to the development of cirrhosis; with the associated 
complications of varices and hepatocellular carcinoma (HCC). 
Genetic Haemochromatosis: what is it? Treatment
• Treatment of GH is to simply to remove iron from the body. 
• This is done by regular phlebotomy known as venesection.  Approximately 
400 to 500ml of blood is removed at one time once commenced can continue 
life-long. 
• Informed, signed consent is usually undertaken for the first venesection to 
explain this, as well as the risk associated with phlebotomy. 
• The main risk although extremely rare is ulna nerve damage. The more 
frequent minor risks are that of potential bruising and discomfort.
There is little research which examines patient’s thoughts and feelings of 
being diagnosed with a life-long disorder which requires life-long treatment in 
the form of venesection and which may lead to cirrhosis of the liver.  
Exploring patient symptoms prior to, and after venesections has not been 
studied fully, nor the implication if they are diagnosed with cirrhosis. 
In the initial phase of the disease venesections are undertaken  weekly for 
many weeks/months. This may have a huge impact re time off work to attend 
treatment, cost of parking at the hospital etc. Understanding the effect of this 
on patients will enable the NHS to improve patient care.
References
Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010; 116(3):317–325. https://doi.org/10.1182/blood-2010-01-261875
Bacon BR, Adams PC, Kowdley KV et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American 
Association for the Study of Liver Diseases. Hepatology. 2011; 54(1):328–343. https://doi.org/10.1002/hep.24330
British Liver Trust. Haemochromatosis. 2017. http://tinyurl.com/y9bwmh4g (accessed 31 October 2017)
European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53(1):3–
22. https://doi.org/10.1016/j.jhep.2010.03.001
Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Inn Intern Med. 2008; 149(4):270. 
https://doi.org/10.7326/0003-4819-149-4-200808190-00009
Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016; 388(10045):706–716. https://doi.org/10.1016/s0140-
6736(15)01315-x
Ulvik RJ. The liver in haemochromatosis. J Trace Elem Med Biol. 2015; 31:219–224. https://doi.org/10.1016/j.jtemb.2014.08.005
• Tiredness, fatigue, lack of energy
• Arthralgia - Pain in the joints especially in the knuckles of the first 2 fingers
• Abdominal pain
• Limb weakness
• Skin pigmentation – bronzing (in association with Type 2 diabetes called  
Bronze diabetes)
• Loss of libido
• Possible impotence or early menopause
• Type 2 diabetes
• Cardiomyopathy
• Fibrosis of the liver or cirrhosis
• Hepatomegaly
• Varices                           (BLT 2017)
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Aims and Objectives of the Study
Aim
To examine the perceptions/perspective and experiences of those living with 
genetic haemochromatosis.
Objectives
• To ascertain how and when patients were first diagnosed with the disease and 
the effect of this on ontological security (patients sense of who they are)
• To examine patients experience of living with the disease and how they have 
had to make adjustments to daily life and work.
• To examine patients experiences of receiving treatment for the disease.
• To provide guidance to the NHS on how to improve patient care for this 
condition
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Picture 2: Venesection equipment
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